Heterocyclic compound as CDK-HDAC double-channel inhibitor
US12415797B2 · kind B2 · utility
0Cited by
0References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 2, 2019 |
| Grant date | Sep 16, 2025 |
| Priority date | — |
| Expiry date | Dec 18, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D487/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides compounds of formula (I) as shown below, including their possible enantiomers and diastereomers, as well as pharmaceutically acceptable salts, hydrates or solvates thereof. The invention also provides pharmaceutical compositions of these compounds, methods for their preparation, and their use in the treatment of diseases and disorders (including cancers).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.